Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).

US House Democrats continue to seek consensus on drug pricing

SOTIO

30/12/2021 | 3 minuty čtení

Vytisknout
Kopírovat odkaz

Nasdaq Biotech Index lost3 % during October. Democrats are scrambling to find a way to include drug price control measures in Build Back Better Act after Medicare drug price setting measures were dropped from compromise legislation released by White House and House Democrats.

Monthly market moves of selected competitors compared to NASDAQ Biotechnology Index (NBI).

biotech10

Area

Company

Ticker

Price range $

Δ Price

MktCap $m

ΔMktCap $m

ADC

ADC Therapeutics

ADCT

23.32 – 28.73

7

%

2,269

143

Immunogen

IMGN

5.78 – 6.04

6

%

1,216

73

Mersana Therapeutics

MRSN

8.35 – 9.59

-9

%

614

-62

Seagen

SGEN

161.86 – 177.79

4

%

32,081

1,188

IL15 / 2

Alkermes

ALKS

28.65 – 32.08

-2

%

4,887

-89

ImmunityBio

IBRX

7.79 – 10.18

-20

%

3,063

-747

Nektar Therapeutics

NKTR

15.92 – 18.41

-16

%

2,786

-515

Xencor

XNCR

33.67-39.69

21

%

2,307

402

CAR-T

Allogene Therapeutics

ALLO

13.13 – 24.52

-33

%

2,451

-1,203

Autolus Therapeutics

AUTL

5.58 – 6.70

-15

%

416

-72

Bellicum Pharma

BLCM

1.99 – 2.89

-30

%

17

-7

Mustang Bio

MBIO

2.12 – 2.64

-17

%

205

-41

Other

Arcus Biosciences

RCUS

31.38 –35.33

-4

%

2,387

-102

Immutep

IMMP

3.64 – 4.66

11

%

278

27

Clovis Oncology

CLVS

4.12 – 4.47

-3

%

513

-15

ADC Therapeutics

ADCT announced its MAA for Zynlonta, a CD19-targeted ADC for the treatment of relapsed or refractory DLBCL, has been validated by EMA. Validation of the application enables the evaluation process by the EMA’s CHMP to begin.

Immunogen

ImmunoGen came out with a quarterly loss of $0.18 per share versus the estimate of a loss of $0.19. This compares to loss of $0.13 per share a year ago.

Mersana Therapeutics

Mersana highlighted new preclinical data for XMT-2056, and immunosynthen STING agonist ADC candidate targeting HER2. The candidate was well tolerated and showed in vivo efficacy as single agent in a SKOV3 HER2 high model. The data were presented at AACR-NCI-EORTC conference.

Seagen

Seagen and Astellas announced the patient enrollment was completed in Cohort K of the phase 1b/2 EV-103 trial. The cohort is evaluating Padcev in combination with Keytruda as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting.

Alkermes

Alkermes announced initiation of ARTISTRY-7, a global Phase 3 trial evaluating the anti-tumor activity and safety of intravenously administered nemvaleukin alfa in combination with Keytruda, compared to chemotherapy, in patients with platinum-resistant ovarian cancer.

ImmunityBio

ImmunityBio announced that papillary disease (Cohort B), the second indication of its QUILT 3.032 Phase 2/3 study of intravesical BCG plus Anktiva in patients with BCG-unresponsive high-grade NMIBC, also met its primary endpoints with disease-free survival of 57% of patients at 12 months. The company has previously reported that the primary endpoint of Cohort A, patients with CIS disease, has been met with a complete response of 72% (58/81).

Nektar Therapeutics

Nektar will announce its financial results for the third quarter 2021 on Thursday, November 4, 2021, after the close of US financial markets.

Xencor

Xencor announced that it is collaborating with Janssen for development and commercialization of plamotamab and XmAb CD28 bispecific antibody combinations to treat patients with B-cell malignancies. Xencor will receive $100 million as upfront payment and $25 million as equity. The company will further be eligible to receive potential milestone payments up to $1.188 billion and royalties on net product sales.

Allogene Therapeutics

Allogene reported that following a report of a chromosomal abnormality in ALLO-501A CAR T cells in a patient treated in the ALPHA2 study, FDA has placed a hold on the Company’s AlloCAR T clinical trials. Allogene expects to provide additional updates in the coming weeks following consultation with the FDA.

Autolus Therapeutics

Autolus announced that it will release its third quarter 2021 financial results and operational highlights before open of US markets on Wednesday, November 3, 2021.

Bellicum Pharmaceuticals

The short interest of Bellicum decreased in September by 26% to 777,729 on October 15, compared to 1,049,113 on September 13.

Mustang Bio

Mustang participated in a fireside chat at Chardan’s Virtual 5th Annual Genetic Medicines Conference, taking place on October 5, 2021.

Arcus Biosciences

The market expects Arcus to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2021. The earnings report might help the stock move higher if the key numbers are better than expectations.

Immutep

Immutep announced it has received positive feedback from EMA regarding its clinical development program for lead product candidate, eftilagimod alpha, including the planned Phase 3 trial in MBC. In its scientific advice EMA has supported the company’s view to continue the development of efti in MBC in Phase 3 clinical trial, based on clinical data presented in December 2020 at SABCS.

Clovis Oncology

Clovis will announce its third quarter 2021 financial results on Wednesday, November 3, 2021, before the open of the US financial markets. The company separately announced lutetium-177 clinical supply agreement with ITM Isotope Technologies.

Sdílet na sociálních sítích

Sdílet na sociálních sítích

Vytisknout

Kopírovat odkaz